For decades, cancer research has been a relentless pursuit of vulnerabilities – weaknesses in tumor cells that can be exploited for targeted therapies. Now, a team at UCSF has unearthed a surprising one: a well-known cancer-causing enzyme, SRC, isn’t just *inside* cancer cells, it’s waving a flag *on the surface*, making it directly accessible to the immune system and antibody-based treatments. This isn’t just a new target; it’s a potential paradigm shift in how we approach a disease that affects nearly half the population.
- SRC’s Unexpected Location: The SRC enzyme, long considered an intracellular driver of cancer, has been found exposed on the surface of multiple tumor types.
- New Therapeutic Avenue: Antibodies targeting SRC, carrying radioactive payloads or immune-stimulating signals, have demonstrated tumor shrinkage in mouse models.
- Broad Applicability: This discovery could impact treatment strategies for up to 50% of all cancers, offering a potential new option for patients with limited alternatives.
SRC Takes an Unexpected Journey to the Cell Surface
The story of SRC is a foundational one in cancer biology. Identified in the 1970s by UCSF researchers J. Michael Bishop and Harold Varmus (a discovery that earned them a Nobel Prize), SRC was the first oncogene identified – a gene capable of transforming a normal cell into a cancerous one. However, previous attempts to target SRC directly with drugs have largely failed. The problem? SRC is vital for normal cell function, so simply blocking it systemically causes unacceptable side effects. This new finding bypasses that issue entirely.
The UCSF team discovered that cancer cells, in their frantic division, generate a significant amount of cellular “garbage.” While healthy cells efficiently recycle this waste, tumor cells become overwhelmed, and the excess is expelled. This expulsion process inadvertently pushes SRC to the cell surface, essentially broadcasting its presence. This isn’t a deliberate strategy by the cancer; it’s a consequence of its chaotic metabolism. The researchers observed this phenomenon in bladder, colorectal, breast, and pancreatic cancer cells, suggesting a widespread mechanism.
Crucially, the team confirmed that SRC was present on tumor cells taken directly from patients, but absent on healthy tissue and immune cells. This specificity is vital – it means targeted therapies are less likely to attack healthy cells, minimizing side effects. The use of both radioactive antibodies and antibodies designed to recruit the immune system demonstrates a versatile approach, opening the door to multiple therapeutic strategies.
The Forward Look: From Bench to Bedside and Beyond
The licensing of the SRC-targeting antibodies to Inversion Therapeutics is the immediate next step. Expect to see preclinical trials accelerate, focusing on safety and dosage optimization. However, the implications extend far beyond these initial antibodies. This discovery validates a broader concept: that previously “undruggable” targets can become accessible through exploiting the cellular stress and waste management systems of cancer cells.
What to watch for: The success of Inversion Therapeutics’ clinical trials will be pivotal. Beyond that, expect a surge in research focused on identifying other proteins that are similarly “excreted” by cancer cells. The field of cancer immunotherapy is already rapidly evolving; this discovery could fuel a new wave of innovation, moving us closer to truly personalized and effective cancer treatments. The challenge now is to determine which other cancers exhibit this same “flagging” behavior and to develop targeted therapies accordingly. This isn’t just about SRC; it’s about unlocking a new understanding of how cancer cells reveal themselves.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
